Approval · Notice of Compliance 34531 · 2024
BIMZELX: Notice of Compliance 34531
Issued December 11, 2024
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 34531
- Date
- December 11, 2024
- Company
- Ucb Canada IncOakville, Ontario, Canada
- Product type
- Biologic
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- New fill volume
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| BIMZELX | Not yet assigned | — |
Medicinal ingredients
- BIMEKIZUMAB 160 MG per ML
- BIMEKIZUMAB 320 MG per 2ML